Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,238 JPY | -2.76% | -5.97% | -11.05% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 8.15 for the current year and 9.67 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.05% | 6.99B | B+ | ||
+20.91% | 43.54B | B- | ||
+16.96% | 21.74B | B+ | ||
+9.05% | 13.53B | - | ||
+7.98% | 13.02B | B+ | ||
+33.80% | 11.28B | B | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+6.64% | 5.09B | B+ | ||
+3.49% | 4.42B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4528 Stock
- Ratings Ono Pharmaceutical Co., Ltd.